These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 20889007)

  • 21. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression.
    Sougioultzis S; Simeonidis S; Bhaskar KR; Chen X; Anton PM; Keates S; Pothoulakis C; Kelly CP
    Biochem Biophys Res Commun; 2006 Apr; 343(1):69-76. PubMed ID: 16529714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.
    McFarland LV
    World J Gastroenterol; 2010 May; 16(18):2202-22. PubMed ID: 20458757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experimental effects of Saccharomyces boulardii on diarrheal pathogens.
    Czerucka D; Rampal P
    Microbes Infect; 2002 Jun; 4(7):733-9. PubMed ID: 12067833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea.
    Katz JA
    J Clin Gastroenterol; 2006 Mar; 40(3):249-55. PubMed ID: 16633131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial.
    Abbas Z; Yakoob J; Jafri W; Ahmad Z; Azam Z; Usman MW; Shamim S; Islam M
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):630-9. PubMed ID: 24722560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interaction of Saccharomyces boulardii with Salmonella enterica serovar Typhimurium protects mice and modifies T84 cell response to the infection.
    Martins FS; Dalmasso G; Arantes RM; Doye A; Lemichez E; Lagadec P; Imbert V; Peyron JF; Rampal P; Nicoli JR; Czerucka D
    PLoS One; 2010 Jan; 5(1):e8925. PubMed ID: 20111723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum.
    Castagliuolo I; LaMont JT; Nikulasson ST; Pothoulakis C
    Infect Immun; 1996 Dec; 64(12):5225-32. PubMed ID: 8945570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A multicenter randomized controlled study of
    Wan CM; Yu H; Liu G; Xu HM; Mao ZQ; Xu Y; Jin Y; Luo RP; Wang WJ; Fang F
    Zhonghua Er Ke Za Zhi; 2017 May; 55(5):349-354. PubMed ID: 28482385
    [No Abstract]   [Full Text] [Related]  

  • 29. Effectiveness and safety of Saccharomyces boulardii for acute infectious diarrhea.
    Dinleyici EC; Eren M; Ozen M; Yargic ZA; Vandenplas Y
    Expert Opin Biol Ther; 2012 Apr; 12(4):395-410. PubMed ID: 22335323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea.
    Szajewska H; Kołodziej M
    Aliment Pharmacol Ther; 2015 Oct; 42(7):793-801. PubMed ID: 26216624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells.
    Dahan S; Dalmasso G; Imbert V; Peyron JF; Rampal P; Czerucka D
    Infect Immun; 2003 Feb; 71(2):766-73. PubMed ID: 12540556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Saccharomyces boulardii ameliorates clarithromycin- and methotrexate-induced intestinal and hepatic injury in rats.
    Duman DG; Kumral ZN; Ercan F; Deniz M; Can G; Cağlayan Yeğen B
    Br J Nutr; 2013 Aug; 110(3):493-9. PubMed ID: 23279717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Probiotic Saccharomyces boulardii CNCM I-745 prevents outbreak-associated Clostridium difficile-associated cecal inflammation in hamsters.
    Koon HW; Su B; Xu C; Mussatto CC; Tran DH; Lee EC; Ortiz C; Wang J; Lee JE; Ho S; Chen X; Kelly CP; Pothoulakis C
    Am J Physiol Gastrointest Liver Physiol; 2016 Oct; 311(4):G610-G623. PubMed ID: 27514478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A prospective control study of
    Zhang DM; Xu BB; Yu L; Zheng LF; Chen LP; Wang W
    Zhonghua Nei Ke Za Zhi; 2017 Jun; 56(6):398-401. PubMed ID: 28592037
    [No Abstract]   [Full Text] [Related]  

  • 35. Influence of
    Stier H; Bischoff SC
    Clin Exp Gastroenterol; 2016; 9():269-279. PubMed ID: 27695355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii.
    Bafutto M; Almeida JR; Leite NV; Costa MB; Oliveira EC; Resende-Filho J
    Arq Gastroenterol; 2013; 50(4):304-9. PubMed ID: 24474234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of Saccharomyces boulardii as a treatment option in IBD.
    Sivananthan K; Petersen AM
    Immunopharmacol Immunotoxicol; 2018 Dec; 40(6):465-475. PubMed ID: 29771163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study.
    Can M; Beşirbellioglu BA; Avci IY; Beker CM; Pahsa A
    Med Sci Monit; 2006 Apr; 12(4):PI19-22. PubMed ID: 16572062
    [